The efficacy and safety of subcutaneous clazakizumab in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate: results from a multinational, phase IIb, randomized, double-blind, placebo/active-controlled, dose-ranging study

Michael E. Weinblatt, Philip Mease, Eduardo Mysler, Tsutomu Takeuchi, Edit Drescher, Alberto Berman, Jun Xing, Moshe Zilberstein, Subhashis Banerjee, Paul Emery

Research output: Contribution to journalArticlepeer-review

52 Citations (Scopus)

Fingerprint

Dive into the research topics of 'The efficacy and safety of subcutaneous clazakizumab in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate: results from a multinational, phase IIb, randomized, double-blind, placebo/active-controlled, dose-ranging study'. Together they form a unique fingerprint.

Medicine & Life Sciences